Yoon Joon-Young, Jeong Won Gi, Choi Yoo-Duk, Kang Seung Ji, Park Hwa Kyung, Oh Hyung-Joo, Park Cheol-Kyu, Oh In-Jae, Kim Young-Chul
Department of Internal Medicine, Division of Pulmonology, Chonnam National University Medical School, Hwasun, Jeonnam, South Korea.
Lung Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, South Korea.
Thorac Cancer. 2025 Jun;16(12):e70111. doi: 10.1111/1759-7714.70111.
Crizotinib, an anaplastic lymphoma kinase (ALK)/ROS1/c-MET inhibitor, improves outcomes in ALK-positive non-small cell lung cancer (NSCLC) but can cause crizotinib-associated renal cysts (CARCs), a rare yet clinically relevant adverse effect. We report a case of a 68-year-old Korean male who developed complex renal cysts after 4 years of crizotinib therapy. Radiologic findings initially raised suspicion for either an abscess or a neoplastic lesion, leading to surgical resection. However, recurrent renal cysts developed during continued crizotinib therapy, and CARCs were subsequently suspected. A dose reduction was implemented, which led to cyst regression without compromising tumor control. This case highlights the need to recognize and manage late-onset toxicities during long-term treatment, emphasizing the clinical value of multidisciplinary evaluation and tailored dose adjustments.
克唑替尼是一种间变性淋巴瘤激酶（ALK）/ROS1/c-MET抑制剂，可改善ALK阳性非小细胞肺癌（NSCLC）的治疗效果，但可能导致克唑替尼相关肾囊肿（CARCs），这是一种罕见但具有临床相关性的不良反应。我们报告了一例68岁的韩国男性病例，该患者在接受克唑替尼治疗4年后出现了复杂性肾囊肿。影像学检查结果最初引发了对脓肿或肿瘤性病变的怀疑，从而导致了手术切除。然而，在继续使用克唑替尼治疗期间，复发性肾囊肿出现，随后怀疑为CARCs。实施了剂量减少，这导致囊肿消退，同时不影响肿瘤控制。该病例强调了在长期治疗期间识别和管理迟发性毒性的必要性，强调了多学科评估和个性化剂量调整的临床价值。
Zotero 插件
